Efficacy and Safety of Sacubitril/Valsartan After Switching From Azilsartan in Essential Hypertensive Patients: Based on Home Blood Pressure Monitoring.

Switching from azilsartan to sacubitril/valsartan significantly reduced morning home blood pressure after 6 months.

• Study population: 27 essential hypertensive patients, mean age 74 years, 48.1% male
• Morning HBP decreased from 144 ± 13/77 ± 13 mmHg at baseline to 128 ± 10/71 ± 9 mmHg after 6 months
• Reduction was statistically significant (p < 0.05 by repeated-measures ANOVA)
• Mean azilsartan dosage at baseline was 27 ± 10 mg/day; mean sacubitril/valsartan dosage after 6 months was 170 ± 47 mg/day

Sacubitril/valsartan treatment significantly reduced NT-proBNP levels after 6 months.

• Median NT-proBNP decreased from 188.2 (IQR 85.3–887.3) pg/mL at baseline to 124.0 (IQR 83.6–696.2) pg/mL after 6 months
• Reduction was statistically significant (p < 0.05 by repeated-measures ANOVA)
• Measurements were taken at baseline and at 3 and 6 months after the start of sacubitril/valsartan treatment

The morning-nighttime difference in systolic home blood pressure was significantly decreased after sacubitril/valsartan treatment.

• 21 out of 27 patients accomplished recording of their nighttime HBP
• Morning-nighttime difference in systolic HBP decreased from 8.8 ± 13.5 mmHg to 3.9 ± 8.5 mmHg
• Reduction was statistically significant (p < 0.05 by repeated-measures ANOVA)

Sacubitril/valsartan was generally well tolerated in hypertensive patients, with the exception of causing hypotension.

• Safety was assessed across 27 essential hypertensive patients over 6 months
• Hypotension was identified as the notable adverse effect
• The paper characterized the overall tolerability as 'generally well tolerated'